Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study

Overview

Journal J Psoriasis Psoriatic Arthritis

Date 2024 Sep 20

PMID 39301091

Authors

Christopher Willy Schwarz

Lone Skov

Alexander Egeberg

Alun Passey

Jennifer Lee

Patricia Gorecki

Nikolai Loft

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level.

Objective: To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year.

Methods: This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries.

Results: In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts.

Conclusion: These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.

Citing Articles

Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study.

Gyldenlove M, Nissen C, Stave S, Thomsen S, Egeberg A, Loft N Am J Clin Dermatol. 2024; 26(1):147-150.

PMID: 39397142 DOI: 10.1007/s40257-024-00897-6.

References

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

Jani M, Barton A, Warren R, Griffiths C, Chinoy H . The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2013; 53(2):213-22. PMC: 3894670. DOI: 10.1093/rheumatology/ket260. View

Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csorgo Z, Boonen H . EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021; 35(2):281-317. DOI: 10.1111/jdv.16926. View

Loft N, Egeberg A, Rasmussen M, Bryld L, Nissen C, Dam T . Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. JAMA Dermatol. 2021; 157(6):676-683. PMC: 8027941. DOI: 10.1001/jamadermatol.2021.0221. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

Sajja A, Joshi A, Teague H, Dey A, Mehta N . Potential Immunological Links Between Psoriasis and Cardiovascular Disease. Front Immunol. 2018; 9:1234. PMC: 5992299. DOI: 10.3389/fimmu.2018.01234. View

Alinaghi F, Calov M, Kristensen L, Gladman D, Coates L, Jullien D . Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018; 80(1):251-265.e19. DOI: 10.1016/j.jaad.2018.06.027. View

Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A . Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. J Eur Acad Dermatol Venereol. 2017; 31(12):2046-2054. DOI: 10.1111/jdv.14406. View

McHugh M . The chi-square test of independence. Biochem Med (Zagreb). 2013; 23(2):143-9. PMC: 3900058. DOI: 10.11613/bm.2013.018. View

10.

Reich K, Blauvelt A, Armstrong A, Langley R, de Vera A, Kolbinger F . Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019; 33(9):1733-1741. DOI: 10.1111/jdv.15637. View

11.

Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C . Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022; 5:CD011535. PMC: 9125768. DOI: 10.1002/14651858.CD011535.pub5. View

12.

Kaushik S, Lebwohl M . Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2018; 80(1):27-40. DOI: 10.1016/j.jaad.2018.06.057. View

13.

Loft N, Egeberg A, Rasmussen M, Bryld L, Nissen C, Dam T . Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study. Acta Derm Venereol. 2020; 101(1):adv00357. PMC: 9309876. DOI: 10.2340/00015555-3722. View

14.

Loft N, Vaengebjerg S, Halling A, Skov L, Egeberg A . Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2019; 34(6):1151-1160. DOI: 10.1111/jdv.16073. View

15.

Warren R, Marsden A, Tomenson B, Mason K, Soliman M, Burden A . Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2018; 180(5):1069-1076. PMC: 6519065. DOI: 10.1111/bjd.16776. View

16.

Yen H, Huang C, Huang I, Hung W, Su H, Yen H . Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP). Br J Dermatol. 2022; 187(2):178-187. DOI: 10.1111/bjd.21047. View

17.

Schwarz C, Loft N, Rasmussen M, Nissen C, Dam T, Ajgeiy K . Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study. Acta Derm Venereol. 2021; 101(10):adv00579. PMC: 9425566. DOI: 10.2340/actadv.v101.351. View

18.

Jensen P, Skov L . Psoriasis and Obesity. Dermatology. 2017; 232(6):633-639. DOI: 10.1159/000455840. View

19.

Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M . Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017; 18(4):583-590. PMC: 5506504. DOI: 10.1007/s40257-017-0274-0. View

20.

Egeberg A, Mallbris L, Gislason G, Skov L, Hansen P . Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study. J Invest Dermatol. 2016; 136(1):93-8. DOI: 10.1038/JID.2015.350. View